No connection

Search Results

PASW

BEARISH
$0.17 Live
Ping An Biomedical Co., Ltd. · NASDAQ
$0.12 52W Range $5.4

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$20.68M
P/E
N/A
ROE
-67.4%
Profit margin
-37.6%
Debt/Equity
0.23
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
90%
PASW presents a classic 'value trap' scenario, characterized by a stable Piotroski F-Score of 5/9 but catastrophic operational decay. While the balance sheet remains relatively clean with low debt and a healthy current ratio, the company has suffered a massive 62% year-over-year revenue collapse and negative profit margins. The 95% decline in share price over the last year reflects a fundamental breakdown in the business model, which is not offset by the low Price-to-Book ratio of 0.51.

Key Strengths

Low Debt/Equity ratio (0.23) indicating minimal leverage
Strong Current Ratio (2.76) suggesting short-term liquidity
Trading significantly below book value (P/B 0.51)
Low Price-to-Sales ratio (0.61)
Recent short-term price stabilization/bounce (+14.5% 1M)

Key Risks

Severe revenue contraction (-62% YoY)
Extremely thin gross margins (2.78%) leaving no room for error
Deeply negative operating margins (-69.64%)
Catastrophic long-term price performance (-95% over 1Y, 3Y, and 5Y)
Micro-cap status ($0.02B) leading to extreme volatility and liquidity risk

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
22
Weak
Value
40
Future
10
Past
5
Health
55
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: Revenue collapse, Negative profitability, Long-term price depreciation
Confidence
95%
Value
40/100

Trades at a deep discount to assets, but assets are not generating returns.

Positives
  • P/B 0.51
  • P/S 0.61
Watchpoints
  • No P/E due to negative earnings
  • Lack of intrinsic value support
Future
10/100

Top-line collapse suggests a failing product line or market loss.

Positives
No standout positives identified.
Watchpoints
  • -62% Revenue Growth
  • Negative ROE
Past
5/100

Consistent and severe destruction of shareholder value over 5 years.

Positives
No standout positives identified.
Watchpoints
  • -95% 1Y Change
  • -95% 5Y Change
Health
55/100

The balance sheet is the only stable component, preventing immediate insolvency.

Positives
  • Piotroski F-Score 5/9
  • Low Debt/Equity
  • Current Ratio 2.76
Watchpoints
  • Negative ROA/ROE
  • Poor Quick Ratio (0.80)
Dividend
0/100

Non-dividend paying company.

Positives
No standout positives identified.
Watchpoints
  • No dividend history
  • 0/100 strength score

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.17

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for PASW and closest competitors.

Updated 2026-04-16
PAS
Ping An Biomedical Co., Ltd.
Primary
5Y
-95.0%
3Y
-95.0%
1Y
-95.0%
6M
-78.2%
1M
+14.5%
1W
+12.2%
REB
Reborn Coffee, Inc.
Peer
5Y
-93.0%
3Y
-61.8%
1Y
-17.5%
6M
+28.7%
1M
+31.9%
1W
+2.7%
REC
Rectitude Holdings Ltd
Peer
5Y
-58.5%
3Y
-58.5%
1Y
-59.4%
6M
-55.2%
1M
+26.6%
1W
+35.0%
REE
REE Automotive Ltd.
Peer
5Y
-99.8%
3Y
-93.9%
1Y
-75.3%
6M
-51.5%
1M
+7.1%
1W
+3.3%
NHT
Natural Health Trends Corp.
Peer
5Y
-21.9%
3Y
-22.1%
1Y
-37.3%
6M
-31.6%
1M
-5.1%
1W
+2.2%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
0.51
P/S Ratio
0.61
EV/Revenue
0.39
EV/EBITDA
-0.91
Market Cap
$20.68M

Profitability

Profit margins and return metrics

Profit Margin -37.57%
Operating Margin -69.64%
Gross Margin 2.78%
ROE -67.43%
ROA -14.67%

Growth

Revenue and earnings growth rates

Revenue Growth -62.0%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.23
Low debt
Current Ratio
2.76
Strong
Quick Ratio
0.8
Poor
Cash/Share
$0.05

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q3 2025

Total Assets
$0.1B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.51x

Consumer Cyclical Sector Comparison

Comparing PASW against 268 companies in the Consumer Cyclical sector (14 bullish, 92 neutral, 162 bearish)
Return on Equity (ROE)
-67.43%
This Stock
vs
-37.91%
Sector Avg
+77.9% (Excellent)
Profit Margin
-37.57%
This Stock
vs
-5.22%
Sector Avg
+619.1% (Superior)
Debt to Equity
0.23
This Stock
vs
1.38
Sector Avg
-83.3% (Less Debt)
Revenue Growth
-62.0%
This Stock
vs
15.01%
Sector Avg
-513.2% (Slower)
Current Ratio
2.76
This Stock
vs
2.39
Sector Avg
+15.3% (Stronger)

Similar Companies

Peer comparison within the same industry

SEC Filings

Recent regulatory filings from the SEC EDGAR database

20-F
ANNUAL REPORT
2026-01-30

PASW filed its annual report on Form 20-F on January 30, 2026. Due to the limited information provided, specific financial highlights and risk factors are not available for summary.

Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning PASW from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile